Clinical and demographic parameter of patients participating in the study
| Diagnosis . | No. . | Age (y) . | Duration (mo) . | ANC (/mm3) . | Hb (g/dL) . | Plts (×103/mm3) . | Therapy . |
|---|---|---|---|---|---|---|---|
| sAA | 4 | 28 ± 10.7 | 5.3 ± 2.5 | 0.9 ± 0.3 | 8.3 ± 0.7 | 25.5 ± 15.6 | Not previously treated except for transfusions |
| mAA | 15 | 33.7 ± 3.3 | 77.1 ± 25.2 | 1.4 ± 0.2 | 10 ± 0.6 | 56.2 ± 9.9 | Supportive, occasional transfusions, 1 patient received danazol |
| sAANR | 19 | 29.7 ± 4.1 | 30.8 ± 8 | 1.0 ± 0.3 | 9 ± 1.0 | 35.4 ± 6.2 | 2 patients treated with cytoxan/CsA; 14 with ATG/CsA; 2 patients treated with ATG/CsA and subsequent cytoxan/CsA; 2 treated with 2 courses of ATG/CsA; of these patients, 3 patients on G-CSF, 1 patient on G-CSF/SCF; 1 patient on G-CSF/EPO |
| recAA | 23 | 39.5 ± 4.2 | 54.4 ± 10.5 | 2.1 ± 0.2 | 11.2 ± 0.5 | 117 ± 13.9 | All patients treated with ATG/CsA; 2 had 2 courses of ATG/CsA; 5 of these patients currently on CsA; in 3 of these patients CsA was restarted; 3 also received androgens |
| PNH | 6 | 39 ± 5.5 | 46 ± 13 | 1.7 ± 0.3 | 8.9 ± 1.6 | 103 ± 29 | Transfusions, courses of steroids |
| Diagnosis . | No. . | Age (y) . | Duration (mo) . | ANC (/mm3) . | Hb (g/dL) . | Plts (×103/mm3) . | Therapy . |
|---|---|---|---|---|---|---|---|
| sAA | 4 | 28 ± 10.7 | 5.3 ± 2.5 | 0.9 ± 0.3 | 8.3 ± 0.7 | 25.5 ± 15.6 | Not previously treated except for transfusions |
| mAA | 15 | 33.7 ± 3.3 | 77.1 ± 25.2 | 1.4 ± 0.2 | 10 ± 0.6 | 56.2 ± 9.9 | Supportive, occasional transfusions, 1 patient received danazol |
| sAANR | 19 | 29.7 ± 4.1 | 30.8 ± 8 | 1.0 ± 0.3 | 9 ± 1.0 | 35.4 ± 6.2 | 2 patients treated with cytoxan/CsA; 14 with ATG/CsA; 2 patients treated with ATG/CsA and subsequent cytoxan/CsA; 2 treated with 2 courses of ATG/CsA; of these patients, 3 patients on G-CSF, 1 patient on G-CSF/SCF; 1 patient on G-CSF/EPO |
| recAA | 23 | 39.5 ± 4.2 | 54.4 ± 10.5 | 2.1 ± 0.2 | 11.2 ± 0.5 | 117 ± 13.9 | All patients treated with ATG/CsA; 2 had 2 courses of ATG/CsA; 5 of these patients currently on CsA; in 3 of these patients CsA was restarted; 3 also received androgens |
| PNH | 6 | 39 ± 5.5 | 46 ± 13 | 1.7 ± 0.3 | 8.9 ± 1.6 | 103 ± 29 | Transfusions, courses of steroids |
Values are mean ± SEM.
ANC indicates absolute neutrophil count; Hb, hemoglobin; sAA, severe aplastic anemia (AA); mAA, moderate AA; sAANR, patients with sAA who relapsed or did not respond to initial therapy; recAA, AA patients who improved after therapy; PNH, paroxysmal nocturnal hemoglobinuria; Plts, platelets; CsA, cyclosporine; ATG, antithymocyte globulin; G-CSF, granulocyte–colony stimulating factor; SCF, stem cell factor; EPO, erythropoietin.